Patent ID: 7141607

Claim:
A method for treating retinal neovascularization in a mammal in need of such treatment, comprising topically administering to the eye a composition capable of delivering a therapeutically effective amount of a compound of formula I to the retina, said composition comprising a polymeric suspension agent which suspends a therapeutic neovascularization inhibitory agent, said therapeutic agent consisting essentially of a compound in the group of formula I: where R 1 represents thienyl, R 2 represents a hydrogen atom or a C 1 –C 6 alkyl, C 1 –C 6 alkenyl, phenyl(C 1 –C 6 ) alkyl, cycloalkyl(C 1 –C 6 )alkyl or cycloalkenyl(C 1 –C 6 )alkyl group, R 3 represents an amino acid side chain or a C 1 –C 6 alkyl, benzyl, (C 1 –C 6 alkoxyl)benzyl or benzyloxy(C 1 –C 6 alkyl) or benzyloxy benzyl group, R 4 represents a hydrogen atom or a C 1 –C 6 alkyl group, R 5 represents a hydrogen atom or a methyl group, n is an integer having the value 0, 1 or 2, and A represents a C 1 –C 6 hydrocarbon chain, optionally substituted with one or more C 1 –C 6 alkyl, phenyl or substituted phenyl groups, or a salt thereof; and a derivative of batimastat formed by methylation halogenation, acetylation, esterification and hydroxylation.